A Post-marketing, Observational, Retrospective, Cohort Study to Assess the Safety of RefortrixTM (Tdap) When Administered During Pregnancy in a Maternal Immunization Program in Brazil.
Phase of Trial: Phase IV
Latest Information Update: 19 Jun 2017
At a glance
- Drugs DTaP vaccine (Primary)
- Indications Diphtheria
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 14 Jun 2017 Status changed from recruiting to completed.
- 16 May 2017 Planned End Date changed from 10 May 2017 to 31 May 2017.
- 16 May 2017 Planned primary completion date changed from 10 May 2017 to 31 May 2017.